% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • novasomes novasomes Apr 12, 2013 4:46 AM Flag

    New technology speeding progress on bird flu vaccine

    CHICAGO (Reuters) - Even as U.S. officials this week awaited the arrival of a sample of the new bird flu virus from China - typically the first step in making a flu vaccine - government-backed researchers had already begun testing a "seed" strain of the virus made from the genetic code posted on the Internet.

    This new, faster approach is the result of a collaboration among the government, vaccine maker Novartis and a unit of the J. Craig Venter Institute, which is using synthetic biology - in which scientists take the genetic code of the virus and use it as a recipe to build the virus from scratch.

    It was an idea born in the aftermath of the 2009 H1N1 pandemic, in which production delays and poor-quality seed strain slowed delivery of the vaccine until October, late enough that people were already sick with swine flu.

    The new method has shaved two weeks off the vaccine-making process. It will take five to six months to ramp up production, but even weeks could make a difference in the case of a potentially deadly flu pandemic, said Robin Robinson, director of the Biomedical Advanced Research and Development Authority or BARDA.

    "We'll take it," said Robinson, whose agency handles pandemic preparedness as part of the U.S. Department of Health and Human Services. "If the virus turns out to be a tough one, that could be very important."

    At least 33 people have been infected and 10 have died from the strain of bird flu known as avian influenza A (H7N9) first found in humans last month. So far, the strain does not appear capable of being passed from person to person.

    But Chinese researchers, in a report published online on Thursday in the New England Journal of Medicine, warned that the sudden emergence of this strain of flu "may pose a serious human health risk" and said "appropriate counter measures were urgently required."


    An especially deadly strain of bird flu in 2003 known as H5N1 had already raised the threat of a global pandemic, spurring more than $2 billion in government contracts to shore up U.S. flu vaccine manufacturing capabilities.

    After the 2009 H1N1 pandemic, U.S. health agencies gathered to do some soul searching. Representatives from BARDA, the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health looked for ways to expedite the process of making flu vaccines, Robinson said.

    These advances would need to apply to all vaccine makers, whether they used the traditional method of growing the virus in live chicken eggs, or the newer methods of growing it in cells or vaccines made from genetically engineered proteins.

    Robinson, who formerly headed the vaccines division at Novavax Inc, had seen firsthand the speed at which a vaccine could be made using synthetic biology during the 2003 outbreak of Severe Acute Respiratory Syndrome or SARS, when companies and governments rushed to make a vaccine.

    So, in 2010, BARDA tapped Novartis, one of its vaccine partners, along with a company owned by Dr. J. Craig Venter, the flamboyant scientist who took part in the race to map the human genome and caused a stir in 2010 when he used synthetic genes to create a custom microbe and bring it life.


    As a test drive for the new flu technology, in 2011 the government gave its partners the genetic sequence for a North American strain of H7N9, a similar virus to the one making people sick in China. "It was just a coincidence," Robinson recalls.

    In less than two weeks, Novartis and Venter's group were ready to make virus seed. The next year, they sequenced an H5N1 virus and produced a synthetic virus in six days.

    Then came a live test. The United States asked its partners to make a real vaccine for a variant of swine flu known as H3N2 that had been infecting children in the U.S. Midwest last year.

    Once again, they produced virus seed in less than a week.

    So, when Chinese health authorities released the genetic sequence for the H7N9 bird flu on March 30, U.S. health officials decided to try the new technique.

    Novartis and Venter's company, Synthetic Genomics Vaccines Inc, went to work and by April 4, they had synthetic DNA ready and had started to grow the virus in cells, long before samples of the actual virus arrived from China on April 11.

    Normally, getting a sample would be the starting point for making a seed virus, which would then be grown and tested to ensure it would grow well in chicken eggs or cells.

    That involves a certain amount of guesswork, however. The new process of building the virus based on its genetic code allows "almost guaranteed success," said Mike Shaw, director of the U.S. Centers for Disease Control and Prevention.

    "That is because you're creating a virus that is almost tailor-made," he said.

    Shaw said the CDC plans to take a vaccine candidate at least to the stage of human safety trials, a process that will take several months.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I can't believe that BARDA has not also asked NVAX to do the same. Surely they have, and we should here that announcement sometime soon. To Jeffg's comment, that gives another vaccine producer all the more reason to acquire NVAX. They must lead or at least stay with the other players. Not to mention, NVAX is on record for having the best pandemic results of any vaccine to date. Lets not forget about that!

      Sentiment: Strong Buy

      • 3 Replies to mewardsb1
      • BARDA of course needs multiple players on the team, by design. They are an independent government agency that looks at ALL the possible capabilities. In this case, given the potential severity, they probably chose Novartis because of their size, global scale, financial resources, etc. This does NOT mean that NVAX is not also doing something with Barda and the Avian flu. Most likely NVAX is engaged in some manner here as well. AND, other big pharma companies like Sanofi, Pfizer, GSK, AZ..........they are probably competitively threatened by Novartis, and would look at NVAX as a potential target to acquire, to advance their capability and speed from seed to delivery. All good.

        Sentiment: Strong Buy

      • Novavax already has a contract with BARDA for "for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza". Check their website. By default, Novavax is involved in pandemic flu vaccine generation. The contract also called for "development of a manufacturing facility plan that has the capability to produce finished vaccine within twelve (12) weeks and at least 50 million doses within six (6) months of an influenza pandemic declaration".

      • Did you not read how fast novartis can make a vaccine?Who needs NVAX?Nobody, thats why the PPS is still 2.50 ish and not 10 bucks.HELLO

    • Too bad for NVAX,Novartis has this technology

6.86+0.59(+9.41%)12:10 PMEDT